Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Arthritis and Rheumatism
Gabor G IlleiPeter E Lipsky

Abstract

To assess the safety of interleukin-6 receptor inhibition and to collect preliminary data on the clinical and immunologic efficacy of tocilizumab in patients with systemic lupus erythematosus (SLE). In an open-label phase I dosage-escalation study, 16 patients with mild-to-moderate disease activity were assigned to receive 1 of 3 doses of tocilizumab given intravenously every other week for 12 weeks (total of 7 infusions): 2 mg/kg in 4 patients, 4 mg/kg in 6 patients, or 8 mg/kg in 6 patients. Patients were then monitored for an additional 8 weeks. The infusions were well tolerated. Tocilizumab treatment led to dosage-related decreases in the absolute neutrophil count, with a median decrease of 38% in the 4 mg/kg dosage group and 56% in the 8 mg/kg dosage group. Neutrophil counts returned to normal after cessation of treatment. One patient was withdrawn from the study because of neutropenia. Infections occurred in 11 patients; none was associated with neutropenia. Disease activity showed significant improvement, with a decrease of > or =4 points in the modified Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index score in 8 of the 15 evaluable patients...Continue Reading

References

Mar 1, 1991·International Immunology·B TangT Kishimoto
Nov 1, 1982·Arthritis and Rheumatism·E M TanR J Winchester
Aug 1, 1994·The Journal of Clinical Investigation·B K FinckD Wofsy
Jul 2, 1998·Clinical and Experimental Immunology·M MiharaY Ohsugi
Nov 6, 2004·Arthritis and Rheumatism·UNKNOWN American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria
Sep 1, 2005·Clinical Reviews in Allergy & Immunology·Tadamitsu Kishimoto
Dec 16, 2005·The New England Journal of Medicine·Michelle PetriUNKNOWN OC-SELENA Trial
Jun 26, 2007·Journal of Clinical Immunology·Hye-Young ChunChang-Hee Suh
Dec 12, 2007·Handbook of Experimental Pharmacology·N Nishimoto, T Kishimoto

❮ Previous
Next ❯

Citations

Nov 7, 2013·Zeitschrift für Rheumatologie·I Kötter, J C Henes
Apr 26, 2011·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Kjell Tullus
Oct 6, 2010·Journal of Clinical Immunology·Aharon KesselElias Toubi
May 15, 2013·Current Rheumatology Reports·Daniel J Wallace
May 30, 2013·Current Rheumatology Reports·Reut Gurion, Nora G Singer
Mar 5, 2013·Drugs·Md Yuzaiful Md Yusof, Paul Emery
Sep 3, 2013·Lancet·Marie Wahren-Herlenius, Thomas Dörner
Jan 11, 2012·Immunology and Cell Biology·Fabien B VincentFabienne Mackay
Jul 22, 2010·Nature Reviews. Rheumatology·Rona M SmithDavid R W Jayne
May 12, 2010·Nature Reviews. Rheumatology·José C CrispínGeorge C Tsokos
May 5, 2010·Nature Reviews. Rheumatology·Lars Rönnblom, Keith B Elkon
Jun 4, 2010·Nature Reviews. Rheumatology·Iñaki Sanz, F Eun-Hyung Lee
Sep 11, 2013·Nature Reviews. Rheumatology·William Stohl
Oct 9, 2013·Nature Reviews. Rheumatology·Aikaterini Thanou, Joan T Merrill
Jul 27, 2011·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Laurie S DavisChandra Mohan
Feb 3, 2011·Rheumatology·Katrine B NorheimRoald Omdal
Dec 20, 2011·Rheumatology·Elisabeth M A Ball, Aubrey L Bell
Apr 20, 2012·Rheumatology·Francisco J García-HernándezJulio Sánchez-Román
Mar 24, 2011·Current Opinion in Rheumatology·Miho Murakami, Norihiro Nishimoto
Nov 2, 2012·Current Opinion in Rheumatology·Roberto Perez-AlvarezUNKNOWN BIOGEAS study group
Apr 23, 2010·Annals of the Rheumatic Diseases·Nienke RoescherGabor G Illei
Apr 24, 2010·Journal of Biomedicine & Biotechnology·Hooi-Ming LeeNorihiro Nishimoto
Mar 16, 2011·Journal of Biomedicine & Biotechnology·Daniel PerryLaurence Morel
Oct 27, 2011·Journal of Biomedicine & Biotechnology·Kim Ohl, Klaus Tenbrock
Oct 27, 2011·Journal of Biomedicine & Biotechnology·Yasunori IwataTakashi Wada
Nov 3, 2011·Arthritis·Misato Hashizume, Masahiko Mihara
Apr 14, 2012·Journal of Biomedicine & Biotechnology·Ding-Lei SuLing-Yun Sun
Apr 14, 2012·International Journal of Rheumatology·Mariana PostalSimone Appenzeller
Jun 16, 2012·International Journal of Rheumatology·Ryusuke YoshimiKeiko Ozato
Aug 8, 2012·Therapeutic Advances in Musculoskeletal Disease·Wen Xiong, Robert G Lahita
May 7, 2013·BMC Medicine·Natasha JordanDavid P D'Cruz
Dec 1, 2010·BMC Medicine·Daniel J Wallace
Feb 26, 2013·Journal of Neuroinflammation·Ettore SalsanoFrancesca L Sciacca
Jan 18, 2011·Arthritis Research & Therapy·Gerd R BurmesterUNKNOWN Kitasato Meeting Faculty
Jul 13, 2011·Arthritis Research & Therapy·Noam Jacob, William Stohl
Nov 15, 2011·Arthritis Research & Therapy·Thomas DörnerPeter E Lipsky
Feb 18, 2011·Molecular Medicine·Christopher M ReillyNilamadhab Mishra
Jul 20, 2010·Immunotherapy·Antonio La Cava
Dec 14, 2011·Immunotherapy·Toshio Tanaka, Tadamitsu Kishimoto
Aug 30, 2013·Medicina oral, patología oral y cirugía bucal·Antonio Bascones-MartinezJukka H Meurman
Nov 9, 2012·International Journal of Biological Sciences·Toshio Tanaka, Tadamitsu Kishimoto
Apr 15, 2014·Drug Design, Development and Therapy·Anjali ShettyNadera J Sweiss
Feb 18, 2014·BMC Medicine·Mariele GattoAndrea Doria

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.